Novartis now expects its core operating profit to grow in the mid to high teens, after second-quarter results outpaced analysts’ expectations, boosted by revenue from its blockbuster treatments.
Related Posts
Sibanye-Stillwater Cuts Guidance, Swings to Wider-Than-Expected Net Loss
Sibanye-Stillwater cut its gold production guidance for the year and posted a swing to a wider net loss than analysts had expected for the half […]
Gap Raises Full-Year Outlook With Strong Start to Holiday Season
The apparel retailer said it now expects full-year sales to grow between 1.5% and 2%. Gap had most recently guided for sales to be up […]
Woodside Ready to Advance Driftwood LNG Selldown Talks
Woodside Energy is seeking to advance talks on the possible sale of a stake in the Driftwood LNG development in the southern U.S. in parallel […]